Literature DB >> 21478273

Endogenous Myc maintains the tumor microenvironment.

Nicole M Sodir1, Lamorna Brown Swigart, Anthony N Karnezis, Douglas Hanahan, Gerard I Evan, Laura Soucek.   

Abstract

The ubiquitous deregulation of Myc in human cancers makes it an intriguing therapeutic target, a notion supported by recent studies in Ras-driven lung tumors showing that inhibiting endogenous Myc triggers ubiquitous tumor regression. However, neither the therapeutic mechanism nor the applicability of Myc inhibition to other tumor types driven by other oncogenic mechanisms is established. Here, we show that inhibition of endogenous Myc also triggers ubiquitous regression of tumors in a simian virus 40 (SV40)-driven pancreatic islet tumor model. Such regression is presaged by collapse of the tumor microenvironment and involution of tumor vasculature. Hence, in addition to its diverse intracellular roles, endogenous Myc serves an essential and nonredundant role in coupling diverse intracellular oncogenic pathways to the tumor microenvironment, further bolstering its credentials as a pharmacological target.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21478273      PMCID: PMC3084025          DOI: 10.1101/gad.2038411

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  29 in total

1.  Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis.

Authors:  G Bergers; R Brekken; G McMahon; T H Vu; T Itoh; K Tamaki; K Tanzawa; P Thorpe; S Itohara; Z Werb; D Hanahan
Journal:  Nat Cell Biol       Date:  2000-10       Impact factor: 28.824

2.  Omomyc, a potential Myc dominant negative, enhances Myc-induced apoptosis.

Authors:  Laura Soucek; Richard Jucker; Laura Panacchia; Ruggero Ricordy; Franco Tatò; Sergio Nasi
Journal:  Cancer Res       Date:  2002-06-15       Impact factor: 12.701

3.  Omomyc expression in skin prevents Myc-induced papillomatosis.

Authors:  L Soucek; S Nasi; G I Evan
Journal:  Cell Death Differ       Date:  2004-09       Impact factor: 15.828

Review 4.  Reflecting on 25 years with MYC.

Authors:  Natalie Meyer; Linda Z Penn
Journal:  Nat Rev Cancer       Date:  2008-12       Impact factor: 60.716

5.  Expression profiling of ductal carcinoma in situ by laser capture microdissection and high-density oligonucleotide arrays.

Authors:  V Luzzi; V Holtschlag; M A Watson
Journal:  Am J Pathol       Date:  2001-06       Impact factor: 4.307

6.  Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes.

Authors:  D Hanahan
Journal:  Nature       Date:  1985 May 9-15       Impact factor: 49.962

7.  Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression.

Authors:  Stella Pelengaris; Michael Khan; Gerard I Evan
Journal:  Cell       Date:  2002-05-03       Impact factor: 41.582

Review 8.  Matrix metalloproteinase inhibitors and cancer: trials and tribulations.

Authors:  Lisa M Coussens; Barbara Fingleton; Lynn M Matrisian
Journal:  Science       Date:  2002-03-29       Impact factor: 47.728

Review 9.  Matrix metalloproteinase inhibitors for cancer therapy:the current situation and future prospects.

Authors:  Barbara Fingleton
Journal:  Expert Opin Ther Targets       Date:  2003-06       Impact factor: 6.902

10.  Modelling Myc inhibition as a cancer therapy.

Authors:  Laura Soucek; Jonathan Whitfield; Carla P Martins; Andrew J Finch; Daniel J Murphy; Nicole M Sodir; Anthony N Karnezis; Lamorna Brown Swigart; Sergio Nasi; Gerard I Evan
Journal:  Nature       Date:  2008-08-17       Impact factor: 49.962

View more
  91 in total

Review 1.  MYC: connecting selective transcriptional control to global RNA production.

Authors:  Theresia R Kress; Arianna Sabò; Bruno Amati
Journal:  Nat Rev Cancer       Date:  2015-09-18       Impact factor: 60.716

2.  Deciphering the Key Features of Malignant Tumor Microenvironment for Anti-cancer Therapy.

Authors:  Bingxue Shang; Gaochuan Zhang; Yanyan Pan; Quansheng Zhou
Journal:  Cancer Microenviron       Date:  2012-05-17

Review 3.  Small-molecule inhibitors of the Myc oncoprotein.

Authors:  Steven Fletcher; Edward V Prochownik
Journal:  Biochim Biophys Acta       Date:  2014-03-19

4.  Tumour microenvironment: target practice.

Authors:  Nicola McCarthy
Journal:  Nat Rev Cancer       Date:  2011-05       Impact factor: 60.716

Review 5.  Target gene-independent functions of MYC oncoproteins.

Authors:  Apoorva Baluapuri; Elmar Wolf; Martin Eilers
Journal:  Nat Rev Mol Cell Biol       Date:  2020-02-18       Impact factor: 94.444

6.  Tracing MYC Expression for Small Molecule Discovery.

Authors:  Jutta Steinberger; Francis Robert; Maxime Hallé; David E Williams; Regina Cencic; Neha Sawhney; Dylan Pelletier; Philip Williams; Yasuhiro Igarashi; John A Porco; Abimael D Rodriguez; Brigitte Kopp; Brian Bachmann; Raymond J Andersen; Jerry Pelletier
Journal:  Cell Chem Biol       Date:  2019-03-14       Impact factor: 8.116

Review 7.  The fine balance of chemokines during disease: trafficking, inflammation, and homeostasis.

Authors:  Sandra M Cardona; Jenny A Garcia; Astrid E Cardona
Journal:  Methods Mol Biol       Date:  2013

8.  Gerometabolites: the pseudohypoxic aging side of cancer oncometabolites.

Authors:  Javier A Menendez; Tomás Alarcón; Jorge Joven
Journal:  Cell Cycle       Date:  2014-02-03       Impact factor: 4.534

9.  Natriuretic peptide receptor A signaling regulates stem cell recruitment and angiogenesis: a model to study linkage between inflammation and tumorigenesis.

Authors:  Jaya Mallela; Sowndharya Ravi; Frantz Jean Louis; Bianca Mulaney; Michael Cheung; Ujjwala Sree Garapati; Vignesh Chinnasamy; Chunyan Wang; Srinivas Nagaraj; Shyam S Mohapatra; Subhra Mohapatra
Journal:  Stem Cells       Date:  2013-07       Impact factor: 6.277

10.  The deubiquitinase USP28 controls intestinal homeostasis and promotes colorectal cancer.

Authors:  Markus E Diefenbacher; Nikita Popov; Sophia M Blake; Christina Schülein-Völk; Emma Nye; Bradley Spencer-Dene; Laura A Jaenicke; Martin Eilers; Axel Behrens
Journal:  J Clin Invest       Date:  2014-06-24       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.